Global plasma protein therapeutics market is projected to show robust growth in the forecast period, 2023-2027, on the account of increased food and drug administration (FDA) approvals for the plasma products across multiple indications. Along with such major factors, increased research and development in the field of developing drugs and treatment procedures out of plasma proteins is driving the growth of the global plasma protein therapeutics market.
Moreover, the market is experiencing a surge in the demand of advanced therapeutic remedies being developed from the plasma protein because of its effective advantages, thereby driving the growth of the market. Furthermore, the government aids toward the advancing healthcare industry and the favorable reimbursement policies by the health policy investment companies which is driving the growth of the market. With the consistent technological advancements towards the extraction and separation of plasma, devising treatment therapeutics out of plasma protein and manufacturing of advanced methods for the administration of these therapeutic treatments is driving the global plasma protein therapeutics market in the upcoming five years.
The global plasma protein therapeutics market is segmented by product, application, end user, competitional landscapes, and regional distribution. Based on product, the market is further fragmented into immunoglobulin, albumin, plasma derived clotting factor, fibrinogen, and others. Immunoglobulin is anticipated to hold the largest market share in the next five years, owing to approval of therapeutic across multiple indications from the FDA, and ease of administration along with the treatment cost. Immunoglobulins are the antibodies that are present in the blood. In case of any infection, or disease manifestation, the human immune system is designed to generate antibodies against the pathogens/ antigens/ stimulant.
These antibodies avail the ability to fight off the infection by counter-attacking the antigens infecting the body. After the infection subsides, the antibodies are stored as memory cells in the human immune system. These antibodies are now called as immunogens /immunoglobulins. These immunoglobulins are utilized by the body to fight the infection in case of re-attack or any later attack. Plasma protein therapeutic procedure extracts these antibodies that are then used as treatment therapeutics for other patients too. Best example being presented in the current treatments of the COVID-19 patients.
Companies holding major shares of the global plasma protein therapeutics market include CSL Behring LLC, Octapharma AG, Grifols S.A., Shire Plc, Bayer AG, Biotest AG, Kedrion S.P.A., China Biologics Products Holdings, Inc., Takeda Pharmaceutical Company Ltd., Baxter International Ltd., Bio Products Laboratory Ltd., ADMA Biologics, Inc., Pfizer Inc., Ferring BV, and HEMA Biologics LLC, among others.
Objective of the Study
- To analyze the historical growth in the market size of the global plasma protein therapeutics market from 2017 to 2021.
- To estimate and forecast the market size of the global plasma protein therapeutics market from 2022 to 2027 and growth rate until 2027.
- To classify and forecast global plasma protein therapeutics market based on product, application, end user, regional distribution, and competitional landscape.
- To identify dominant region or segment in the global plasma protein therapeutics market.
- To identify drivers and challenges for global plasma protein therapeutics market.
- To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global plasma protein therapeutics market.
- To identify and analyze the profile of leading players operating in global plasma protein therapeutics market.
- To identify key sustainable strategies adopted by market players in global plasma protein therapeutics market.
Click here to download the sample
TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers, suppliers, and service providers across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufactures which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufactures, distribution channels and presence of all major players across the country.
TechSci Research calculated the market size of global plasma protein therapeutics market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.
Key Target Audience
- Manufacturers, end users, service providers and other stakeholders
- Distributers and suppliers of products and other stakeholders
- Organizations, forums, and alliances related to plasma protein therapeutics market
- Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as vendors, suppliers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
| Attribute | Details |
| Base Year | 2021 |
| Historical Years | 2017 – 2020 |
| Estimated Year | 2022 |
| Forecast Period | 2023 – 2027 |
| Quantitative Units | Revenue in USD Million and CAGR for 2017-2021 and 2022-2027 |
| Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | - Product
- Application
- End User
|
| Regional Scope | North America; Asia Pacific; Europe & CIS; South America; Middle East & Africa |
| Country Scope | United States; Canada; Mexico; China; India; Japan; South Korea; Australia; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; Saudi Arabia; UAE; South Africa |
| Key Companies Profiled | CSL Behring LLC, Octapharma AG, Grifols S.A., Shire Plc, Bayer AG, Biotest AG, Kedrion S.P.A., China Biologics Products Holdings, Inc., Takeda Pharmaceutical Company Ltd., Baxter International Ltd., Bio Products Laboratory Ltd., ADMA Biologics, Inc., Pfizer Inc., Ferring BV, and HEMA Biologics LLC. |
| Customization Scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
